Quanterix (NASDAQ:QTRX) Announces Earnings Results, Misses Estimates By $0.22 EPS

Quanterix (NASDAQ:QTRX) announced its quarterly earnings data on Monday. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.22), FiscalAI reports. Quanterix had a negative net margin of 73.47% and a negative return on equity of 21.34%. The business had revenue of $41.40 million for the quarter, compared to analysts’ expectations of $37.95 million.

Quanterix Price Performance

Shares of QTRX stock traded down $0.22 on Monday, hitting $6.33. The stock had a trading volume of 367,808 shares, compared to its average volume of 669,145. The company’s 50 day moving average price is $6.52 and its 200-day moving average price is $5.99. Quanterix has a 1 year low of $4.05 and a 1 year high of $8.77. The firm has a market capitalization of $295.68 million, a P/E ratio of -2.72 and a beta of 1.09.

Analyst Upgrades and Downgrades

QTRX has been the subject of a number of analyst reports. Canaccord Genuity Group upped their price target on Quanterix from $5.00 to $8.00 and gave the company a “hold” rating in a research report on Monday, December 22nd. Wall Street Zen upgraded Quanterix from a “sell” rating to a “hold” rating in a report on Monday, December 29th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Quanterix in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Quanterix presently has a consensus rating of “Hold” and a consensus price target of $11.33.

Institutional Trading of Quanterix

A number of institutional investors and hedge funds have recently bought and sold shares of QTRX. Ameriprise Financial Inc. boosted its stake in shares of Quanterix by 14.0% in the second quarter. Ameriprise Financial Inc. now owns 4,236,877 shares of the company’s stock valued at $28,175,000 after purchasing an additional 521,639 shares during the period. Vanguard Group Inc. lifted its holdings in Quanterix by 4.7% during the 3rd quarter. Vanguard Group Inc. now owns 2,647,515 shares of the company’s stock worth $14,376,000 after buying an additional 118,565 shares in the last quarter. Millennium Management LLC boosted its position in Quanterix by 9,880.2% in the 3rd quarter. Millennium Management LLC now owns 1,209,199 shares of the company’s stock valued at $6,566,000 after buying an additional 1,197,083 shares during the period. Geode Capital Management LLC grew its stake in shares of Quanterix by 6.1% in the fourth quarter. Geode Capital Management LLC now owns 1,073,967 shares of the company’s stock worth $6,832,000 after acquiring an additional 62,077 shares in the last quarter. Finally, State Street Corp increased its position in shares of Quanterix by 9.0% during the fourth quarter. State Street Corp now owns 893,401 shares of the company’s stock worth $5,682,000 after acquiring an additional 73,867 shares during the period. 86.48% of the stock is currently owned by hedge funds and other institutional investors.

Quanterix Company Profile

Quanterix Corporation is a life sciences and diagnostics company specializing in ultra-sensitive digital immunoassay platforms. Its proprietary Single Molecule Array (Simoa) technology enables researchers to detect and quantify proteins, peptides and nucleic acids at femtomolar concentrations, offering sensitivity that surpasses traditional immunoassay methods. By translating single-molecule detection into routine laboratory workflows, Quanterix aims to accelerate biomarker discovery and the development of novel diagnostics and therapeutics.

The company’s core product portfolio includes the Simoa HD-1 and HD-X Analyzers, which automate high-throughput digital immunoassays for quantifying low-abundance biomarkers.